Regentis Biomaterials Ltd. is advancing its GelrinC hydrogel technology, a cell-free, off-the-shelf implant designed to regenerate durable, natural-like cartilage in patients with painful knee cartilage injuries. The implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, and the company has reported greater pain improvement than traditional microfracture.
The company has treated 43 of 80 planned patients in its U.S. pivotal Phase III trial, with enrollment expected to conclude around the end of 2026. Regentis is also preparing for potential European commercialization under its existing CE Mark approval. In a significant manufacturing development, the company is scaling production following European regulatory approval of a new solvent-free process that it says increases production yield by 400%. This scale-up is critical as Regentis positions itself to supply the European market and, eventually, the U.S. market if its pivotal trial succeeds.
GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The technology’s potential to offer a minimally invasive, off-the-shelf solution could reduce surgical complexity and recovery times compared with current treatments. For investors, the manufacturing milestone and trial progress represent key operational steps toward commercialization.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company’s lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
The announcement comes as Regentis continues to execute on its clinical and manufacturing timelines. For more details, view the full article at https://nnw.fm/JiVLN. The latest news and updates relating to Regentis are available in the company’s newsroom at https://nnw.fm/RGNT. This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement.
About NetworkNewsWire: NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. Please see full terms of use and disclaimers on the NetworkNewsWire website: https://www.NetworkNewsWire.com/Disclaimer.
